We hypothesized that the combination of GEM with MG-132, Dasatinib, Shikonin, Midostaurin, MS-275, and Z-LLNle-CHO may target CALB2 or GPX3 for CRC. This evidence concerns the gene GPX3 and colorectal carcinoma.